The Democratic Congress' Witness List
This article was originally published in RPM Report
Executive Summary
Democrats are calling on some familiar faces to testify before Congress on Medicare Part D drug prices and FDA drug safety reforms.
You may also be interested in...
The Politics of Drug Safety: An FDA Whistleblower's Push for Reform
FDA official David Graham went on Capitol Hill to discuss his view of what's wrong with the drug safety review process. He gained acclaim during the Vioxx aftermath, and proved he still has an avid following in Congress.
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.
Designer Labeling: Drug Safety Reform Proposals Include New Powers for FDA
The time has come when the pharmaceutical industry will have to answer for Vioxx. Congress will address drug safety in 2007. That means FDA could get new authority over the heart and soul of any new drug-the label.